Pamela Bush, Ph.D., MBA, Joins Predictive Oncology as SVP of Strategic Sales and Business Development
December 07 2021 - 08:30AM
Predictive Oncology, (POAI), a knowledge-driven company focused on
applying artificial intelligence (AI) to develop personalized
cancer therapies, today announced that Pamela Bush, Ph.D., MBA
would be joining the company’s leadership team as SVP of Strategic
Sales and Business Development. Bush brings nearly two decades of
experience in business development and consulting to POAI’s
leadership team and stands ready to commercialize its
groundbreaking cancer research technologies.
“Pamela’s track record of innovative and collaborative
leadership positions fit perfectly as we begin to commercialize our
technologies,” said J. Melville (“Mel”) Engle, CEO and Chairman of
Predictive Oncology. “Pamela will build on the work we’ve already
begun in establishing the most advanced solution for predicting
cancer treatment outcomes, supporting pharmaceutical companies and
healthcare organizations in applications from drug discovery to
optimizing patient care.”
“Predictive Oncology has focused on bringing together multiple
novel technologies and research approaches to predict treatment
outcomes for drug formulations in cancer patients,” Bush said. “I’m
looking forward to bringing these capabilities to the market as
soon as possible and working with our partners to make it the new
gold standard of cancer research. The world has waited long enough
for a targeted method devised to eliminate cancer.”
In addition to her sales role, Bush will work with the company’s
senior leadership team to identify opportunities for business
development, including additional acquisitions and licensing
agreements. She will also serve to further integrate POAI’s new
acquisition of zPREDICTA into the company.
Before coming to Predictive Oncology, Bush served as the
Director of Immunology at Lilly Patient Services, Eli Lilly &
Company, primarily focusing on managing vendor performance and
relationships, as well as negotiating contracts and finding
workflow efficiencies. Before that, Bush served as Director of
Corporate Business Development at Eli Lilly & Company, focusing
on coordinating cross-functional teams. Bush was also the founder
and managing partner of BluGene Consulting, a consultancy focused
on emerging life science companies that focused on new client
acquisition and private investor fundraising.
About Predictive Oncology
Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven
company focused on applying artificial intelligence (AI) to develop
personalized cancer therapies, which can lead to more effective
treatments and improved patient outcomes. Using artificial
intelligence, Predictive Oncology uses a database of 150,000+
cancer tumors, categorized by patient type, against drug compounds
to determine optimal therapies to be used to ultimately eliminate
cancer.
As the drug discovery community has now realized, a
genomics-based approach to cancer research and drug development is
insufficient to achieve the promise of personalized therapeutics.
Predictive Oncology instead takes a multiomic approach, which
considers the vast multitude of factors that make each cancer
unique. Rather than operating based on the equivalent of a birds’
eye view, Predictive Oncology makes possible a more personalized
and effective approach to cancer research and treatment.
Forward-Looking Statements: Certain matters discussed in this
release contain forward-looking statements. These forward-looking
statements reflect our current expectations and projections about
future events and are subject to substantial risks, uncertainties
and assumptions about our operations and the investments we make.
All statements, other than statements of historical facts, included
in this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact: Landon Capital Keith Pinder (404)
995-6671 kpinder@landoncapital.net
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4b6a619d-1efa-4428-8509-cfd4a62e6127
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2023 to Mar 2024